<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00419744</url>
  </required_header>
  <id_info>
    <org_study_id>D589CC00003</org_study_id>
    <nct_id>NCT00419744</nct_id>
  </id_info>
  <brief_title>A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD</brief_title>
  <official_title>A Phase IIIB, 12-Month, Double-blind, Double-dummy,Randomised, Parallel-group, Multicentre Exacerbation Study of SYMBICORT® pMDI 160/4.5 μg x 2 Actuations Twice-daily and 80/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler® 4.5 μg x 2 Inhalations Twice-daily in COPD Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if SYMBICORT® delivered via a pressurized
      metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year</measure>
    <time_frame>12 months</time_frame>
    <description>Number of COPD-related exacerbations per patient-treatment year. COPD-related exacerbation was defined as worsening COPD that required a course of oral steriods for treatment and/or hospitalization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Exacerbations Per Subject-year</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of exacerbations per subject-year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-dose Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in pre-dose FEV1 from baseline to the average of the randomized treatment period, as calculated by averaging treatment period FEV1 values and subtracting the pre-dose value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Peak Expiratory Flow (PEF)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in morning PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline morning PEF value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEF</measure>
    <time_frame>12 months</time_frame>
    <description>Change in evening PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline evening PEF value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea Symptom Scores</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline of Dyspnea symptoms evaluated using the breathlessness diary, a 5-point Likert-type scale, ranging from 0 to 4 with higher scores indicating a more severe manifestation of the Dyspnea symptom. Change from baseline was calculated by averaging treatment period Dyspnea scores and subtracting the baseline Dyspnea scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medication</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in the use of beta-2 agonists, as calculated by averaging treatment period inhalations per day and subtracting the baseline number of inhalations per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ) Score</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in the SGRQ overall score, as calculated by averaging treatment period SGRQ scores and subtracting the baseline SGRQ scores. The SGRQ contains 3 domains: Symptoms (distress due to respiratory symptoms, 8 questions), Activity (disturbance of physical activity, 16 questions), and Impacts (overall impact on daily life and well-being, 26 questions). Lower scores are associated with less severe symptoms.</description>
  </secondary_outcome>
  <enrollment type="Actual">1200</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/formoterol (SYMBICORT) pMDI</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Turbuhaler</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A current clinical diagnosis of COPD with COPD symptoms for more than 2 years

          -  Current smoker or smoking history of 10 or more pack years (1 pack year = 20
             cigarettes smoked per day for one year)

          -  A history of at least 1 COPD exacerbations requiring a course of steroids and/or
             antibiotics within 1-12 months before the first visit

        Exclusion Criteria:

          -  A history of asthma at or after 18 years of age

          -  A history of allergic rhinitis at or after 18 years of age

          -  Subjects taking oral steroids

          -  Any significant disease or disorder that may jeopardize a subject's safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christer Hultquist, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Foothill Ranch</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Banos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sepulveda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stanford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Opalocka</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Cloud</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coeur D'alene</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Witchita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sunset</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronxville</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elmira</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Larchmont</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chardon</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bensalem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Downingtown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Landsdale</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warminster</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prosperity</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fayetteville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>9 de Julio</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mar Del Plata</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ramos Mejia</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vicente Lopez</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Juan</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porta Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florian�polis</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo Andre</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valparaiso</city>
        <state>Quinta Region</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rancagua</city>
        <state>Vi Region</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medillin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barranquilla</city>
        <state>Atl�ntico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota Dc</city>
        <state>Cundianmarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jesus Maria</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Borja</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Surco</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belvilee</city>
        <state>Cape Town</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tygerberg</city>
        <state>Cape Town</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Elizabeth</city>
        <state>E Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Korsten</city>
        <state>Port Elizabeth</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Groenkloof</city>
        <state>Pretoria</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thaba Tswane</city>
        <state>Pretoria</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amanzimtoti</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boksburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Centurion</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Humansdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pretoria West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roodepoort</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Distrito Capital</city>
        <state>Caracas</state>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>United States</country>
    <country>Venezuela</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2007</study_first_submitted>
  <study_first_submitted_qc>January 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2007</study_first_posted>
  <results_first_submitted>August 18, 2010</results_first_submitted>
  <results_first_submitted_qc>August 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 16, 2010</results_first_posted>
  <last_update_submitted>August 18, 2010</last_update_submitted>
  <last_update_submitted_qc>August 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2010</last_update_posted>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient randomized on 02 January 2007. The last patient completed study on 27 August 2009. The study randomized patients in the United States and Mexico (93 investigational sites), South America (48 investigational sites), and South Africa (20 investigational sites).</recruitment_details>
      <pre_assignment_details>The study consisted of an initial screening visit (Visit 1) and 2-week run-in enrollment visits (Visits 2 and 3) prior to being randomized to 1 of 3 treatment groups</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SYM 160/4.5 X 2 BID</title>
          <description>SYMBICORT pMDI (budesonide/formoterol) 160/4.5 μg (delivered dose) per actuation, 2 actuations administered twice daily (BID)</description>
        </group>
        <group group_id="P2">
          <title>SYM 80/4.5 X 2 BID</title>
          <description>SYMBICORT pMDI (budesonide/formoterol) 80/4.5 μg (delivered dose) per actuation, 2 actuations administered BID</description>
        </group>
        <group group_id="P3">
          <title>FOR 4.5 X 2 BID</title>
          <description>Formoterol Turbuhaler 4.5 μg x 2 inhalations BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="407"/>
                <participants group_id="P2" count="408"/>
                <participants group_id="P3" count="404"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="290"/>
                <participants group_id="P3" count="271"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="118"/>
                <participants group_id="P3" count="133"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized in error</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moving out of state</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Spirometry mouthpiece issues</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect medication kit dispensed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SYM 160/4.5 X 2 BID</title>
          <description>SYMBICORT pMDI (budesonide/formoterol) 160/4.5 μg (delivered dose) per actuation, 2 actuations administered twice daily (BID)</description>
        </group>
        <group group_id="B2">
          <title>SYM 80/4.5 X 2 BID</title>
          <description>SYMBICORT pMDI (budesonide/formoterol) 80/4.5 μg (delivered dose) per actuation, 2 actuations administered BID</description>
        </group>
        <group group_id="B3">
          <title>FOR 4.5 X 2 BID</title>
          <description>Formoterol Turbuhaler 4.5 μg x 2 inhalations BID</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="407"/>
            <count group_id="B2" value="408"/>
            <count group_id="B3" value="403"/>
            <count group_id="B4" value="1218"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.8" spread="9.4"/>
                    <measurement group_id="B2" value="62.8" spread="9.22"/>
                    <measurement group_id="B3" value="62.5" spread="9.36"/>
                    <measurement group_id="B4" value="63.0" spread="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="174"/>
                    <measurement group_id="B4" value="463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="264"/>
                    <measurement group_id="B3" value="229"/>
                    <measurement group_id="B4" value="755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year</title>
        <description>Number of COPD-related exacerbations per patient-treatment year. COPD-related exacerbation was defined as worsening COPD that required a course of oral steriods for treatment and/or hospitalization.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SYM 160/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 160/4.5 μg (delivered dose) per actuation, 2 actuations administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>SYM 80/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 80/4.5 μg (delivered dose) per actuation, 2 actuations administered BID</description>
          </group>
          <group group_id="O3">
            <title>FOR 4.5 X 2 BID</title>
            <description>Formoterol Turbuhaler 4.5 μg x 2 inhalations BID</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year</title>
          <description>Number of COPD-related exacerbations per patient-treatment year. COPD-related exacerbation was defined as worsening COPD that required a course of oral steriods for treatment and/or hospitalization.</description>
          <units>Exacerbations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="403"/>
                <count group_id="O3" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75"/>
                    <measurement group_id="O2" value="0.84"/>
                    <measurement group_id="O3" value="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Change in pre-dose FEV1 from baseline to the average of the randomized treatment period, as calculated by averaging treatment period FEV1 values and subtracting the pre-dose value.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SYM 160/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 160/4.5 μg (delivered dose) per actuation, 2 actuations administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>SYM 80/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 80/4.5 μg (delivered dose) per actuation, 2 actuations administered BID</description>
          </group>
          <group group_id="O3">
            <title>FOR 4.5 X 2 BID</title>
            <description>Formoterol Turbuhaler 4.5 μg x 2 inhalations BID</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Change in pre-dose FEV1 from baseline to the average of the randomized treatment period, as calculated by averaging treatment period FEV1 values and subtracting the pre-dose value.</description>
          <units>Liters (L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="399"/>
                <count group_id="O3" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.18"/>
                    <measurement group_id="O2" value="0.07" spread="0.17"/>
                    <measurement group_id="O3" value="0.04" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Peak Expiratory Flow (PEF)</title>
        <description>Change in morning PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline morning PEF value.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SYM 160/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 160/4.5 μg (delivered dose) per actuation, 2 actuations administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>SYM 80/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 80/4.5 μg (delivered dose) per actuation, 2 actuations administered BID</description>
          </group>
          <group group_id="O3">
            <title>FOR 4.5 X 2 BID</title>
            <description>Formoterol Turbuhaler 4.5 μg x 2 inhalations BID</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Peak Expiratory Flow (PEF)</title>
          <description>Change in morning PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline morning PEF value.</description>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="397"/>
                <count group_id="O3" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.82" spread="37.96"/>
                    <measurement group_id="O2" value="19.61" spread="38.83"/>
                    <measurement group_id="O3" value="15.81" spread="41.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEF</title>
        <description>Change in evening PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline evening PEF value.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SYM 160/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 160/4.5 μg (delivered dose) per actuation, 2 actuations administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>SYM 80/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 80/4.5 μg (delivered dose) per actuation, 2 actuations administered BID</description>
          </group>
          <group group_id="O3">
            <title>FOR 4.5 X 2 BID</title>
            <description>Formoterol Turbuhaler 4.5 μg x 2 inhalations BID</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEF</title>
          <description>Change in evening PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline evening PEF value.</description>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="400"/>
                <count group_id="O2" value="397"/>
                <count group_id="O3" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.62" spread="37.86"/>
                    <measurement group_id="O2" value="17.77" spread="37.67"/>
                    <measurement group_id="O3" value="14.08" spread="41.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnea Symptom Scores</title>
        <description>Change from baseline of Dyspnea symptoms evaluated using the breathlessness diary, a 5-point Likert-type scale, ranging from 0 to 4 with higher scores indicating a more severe manifestation of the Dyspnea symptom. Change from baseline was calculated by averaging treatment period Dyspnea scores and subtracting the baseline Dyspnea scores.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SYM 160/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 160/4.5 μg (delivered dose) per actuation, 2 actuations administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>SYM 80/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 80/4.5 μg (delivered dose) per actuation, 2 actuations administered BID</description>
          </group>
          <group group_id="O3">
            <title>FOR 4.5 X 2 BID</title>
            <description>Formoterol Turbuhaler 4.5 μg x 2 inhalations BID</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea Symptom Scores</title>
          <description>Change from baseline of Dyspnea symptoms evaluated using the breathlessness diary, a 5-point Likert-type scale, ranging from 0 to 4 with higher scores indicating a more severe manifestation of the Dyspnea symptom. Change from baseline was calculated by averaging treatment period Dyspnea scores and subtracting the baseline Dyspnea scores.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="400"/>
                <count group_id="O3" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.65"/>
                    <measurement group_id="O2" value="-0.29" spread="0.70"/>
                    <measurement group_id="O3" value="-0.24" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue Medication</title>
        <description>Change from baseline in the use of beta-2 agonists, as calculated by averaging treatment period inhalations per day and subtracting the baseline number of inhalations per day.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SYM 160/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 160/4.5 μg (delivered dose) per actuation, 2 actuations administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>SYM 80/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 80/4.5 μg (delivered dose) per actuation, 2 actuations administered BID</description>
          </group>
          <group group_id="O3">
            <title>FOR 4.5 X 2 BID</title>
            <description>Formoterol Turbuhaler 4.5 μg x 2 inhalations BID</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Rescue Medication</title>
          <description>Change from baseline in the use of beta-2 agonists, as calculated by averaging treatment period inhalations per day and subtracting the baseline number of inhalations per day.</description>
          <units>Number of inhalations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="401"/>
                <count group_id="O3" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="3.57"/>
                    <measurement group_id="O2" value="-1.03" spread="3.74"/>
                    <measurement group_id="O3" value="-0.28" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St. George's Respiratory Questionnaire (SGRQ) Score</title>
        <description>Change from baseline in the SGRQ overall score, as calculated by averaging treatment period SGRQ scores and subtracting the baseline SGRQ scores. The SGRQ contains 3 domains: Symptoms (distress due to respiratory symptoms, 8 questions), Activity (disturbance of physical activity, 16 questions), and Impacts (overall impact on daily life and well-being, 26 questions). Lower scores are associated with less severe symptoms.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SYM 160/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 160/4.5 μg (delivered dose) per actuation, 2 actuations administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>SYM 80/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 80/4.5 μg (delivered dose) per actuation, 2 actuations administered BID</description>
          </group>
          <group group_id="O3">
            <title>FOR 4.5 X 2 BID</title>
            <description>Formoterol Turbuhaler 4.5 μg x 2 inhalations BID</description>
          </group>
        </group_list>
        <measure>
          <title>St. George's Respiratory Questionnaire (SGRQ) Score</title>
          <description>Change from baseline in the SGRQ overall score, as calculated by averaging treatment period SGRQ scores and subtracting the baseline SGRQ scores. The SGRQ contains 3 domains: Symptoms (distress due to respiratory symptoms, 8 questions), Activity (disturbance of physical activity, 16 questions), and Impacts (overall impact on daily life and well-being, 26 questions). Lower scores are associated with less severe symptoms.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="366"/>
                <count group_id="O3" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.23" spread="14.72"/>
                    <measurement group_id="O2" value="-5.00" spread="16.10"/>
                    <measurement group_id="O3" value="-5.71" spread="15.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Exacerbations Per Subject-year</title>
        <description>Rate of exacerbations per subject-year</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SYM 160/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 160/4.5 μg (delivered dose) per actuation, 2 actuations administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>SYM 80/4.5 X 2 BID</title>
            <description>SYMBICORT pMDI (budesonide/formoterol) 80/4.5 μg (delivered dose) per actuation, 2 actuations administered BID</description>
          </group>
          <group group_id="O3">
            <title>FOR 4.5 X 2 BID</title>
            <description>Formoterol Turbuhaler 4.5 μg x 2 inhalations BID</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Exacerbations Per Subject-year</title>
          <description>Rate of exacerbations per subject-year</description>
          <units>Rate</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="403"/>
                <count group_id="O3" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.639"/>
                    <measurement group_id="O2" value="0.745"/>
                    <measurement group_id="O3" value="1.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SYM 160/4.5 X 2 BID</title>
          <description>SYMBICORT pMDI (budesonide/formoterol) 160/4.5 μg (delivered dose) per actuation, 2 actuations administered twice daily (BID)</description>
        </group>
        <group group_id="E2">
          <title>SYM 80/4.5 X 2 BID</title>
          <description>SYMBICORT pMDI (budesonide/formoterol) 80/4.5 μg (delivered dose) per actuation, 2 actuations administered BID</description>
        </group>
        <group group_id="E3">
          <title>FOR 4.5 X 2 BID</title>
          <description>Formoterol Turbuhaler 4.5 μg x 2 inhalations BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cor Pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Aortic Valve Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Atrial Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Right Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Gastritis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Gastroduodenal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pancreatitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Jaundice Cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Bronchitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Enterocolitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pneumonia Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pneumonia Staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Drug Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Collapse Of Lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Dislocation Of Joint Prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chondrocalcinosis Pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Metastatic Bronchial Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Non-Small Cell Lung Cancer Stage Iii</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Oesophageal Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Oesophageal Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Mesothelioma Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Metastatic Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Non-Small Cell Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Thyroid Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Anxiety Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urethral Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Renal Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Renal Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pulmonary Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Bronchial Secretion Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Laryngeal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Arterial Thrombosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Iliac Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Intermittent Claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="193" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="176" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may use the Multi-Center Study Results and the Site Data for the limited purpose of his or her own research and academic analysis until the earlier of the publication of the first Multi-center Publication and the second anniversary of the completion of the Multi-center Study at all participating sites.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

